Dimension Capital is a New York and San Francisco-based multistage venture firm founded in late 2022 by Zavain Dar, Adam Goulburn, and Nan Li, all formerly of Lux Capital and Obvious Ventures. The firm was built on the conviction that the boundary between life sciences investing and frontier software investing has effectively dissolved, and that the most important companies at this intersection require investors with genuine technical depth at both the model layer and the biology layer. In under four years, the firm has grown to $1.65B in AUM across three funds, a pace normally reserved for firms with a decade of distributions.
Dimension backs companies at the intersection of science and compute: AI for biology, drug discovery, materials science research, lab automation, and adjacent hardware and infrastructure.
The firm is multistage and research-oriented, willing to co-lead seed rounds in companies with no revenue and no clinical asset where the core product is a foundation model, and following on aggressively through later rounds in its strongest positions.
Dimension Capital I:
Launched in 2022 with $350 million, focusing on early-stage investments in drug discovery, life sciences, machine learning, artificial intelligence, advanced manufacturing, and software sectors.
Dimension Capital II:
Closed in October 2024, raising $500 million to continue investing in startups at the intersection of technology and biology. This fund exceeded its $400 million target, reflecting strong investor interest.
Dimension III:
Closed at $800M in July 2026.
Leadership
Zavain Dar is Co-Founder and General Partner, a Stanford University graduate and former partner at Lux Capital. Adam Goulburn is Co-Founder and General Partner, a Monash University graduate and former partner at Lux Capital, based in New York. Nan Li is Co-Founder and General Partner, formerly of Obvious Ventures. Simon Barnett is Partner. Additional team members include Michele Vlcek, Amy Zhen, and Chloe Gonzalez.
Investment Strategy
Dimension operates as a multistage, research-led firm, seeding companies before their categories exist and defending ownership through large follow-on rounds.
The three-partner structure is deliberate: a small partnership with genuine technical literacy at the model layer can move faster and with more conviction on seed rounds in novel scientific categories than committees can.
The firm is unusually comfortable with pre-revenue, pre-clinical risk where the defensible asset is a model, a dataset, or an automated experimental loop.
Its multistage structure enables it to write $30M seed checks and then participate in $400M Series C rounds without syndicating away the position.
Notable Investments
Notable Exits
Zavain Dar — Co-Founder & General Partner
zavain@dimensioncap.com
Adam Goulburn — Co-Founder & General Partner
adam@dimensioncap.com
Nan Li — Co-Founder & General Partner
United States
